SG10201408392PA - Methods of determining patient response by measurement of her-3 - Google Patents

Methods of determining patient response by measurement of her-3

Info

Publication number
SG10201408392PA
SG10201408392PA SG10201408392PA SG10201408392PA SG10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA SG 10201408392P A SG10201408392P A SG 10201408392PA
Authority
SG
Singapore
Prior art keywords
methods
measurement
patient response
determining patient
determining
Prior art date
Application number
SG10201408392PA
Other languages
English (en)
Inventor
Michael Bates
Jennifer W Cook
Gundo Diedrich
Laurie Goodman
Ali Mukherjee
Gordon Parry
Jeff Sperinde
Stephen John Williams
Original Assignee
Lab Corp America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Corp America Holdings filed Critical Lab Corp America Holdings
Publication of SG10201408392PA publication Critical patent/SG10201408392PA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201408392PA 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3 SG10201408392PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US17663009P 2009-05-08 2009-05-08
US18796209P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
SG10201408392PA true SG10201408392PA (en) 2015-01-29

Family

ID=42340114

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201408392PA SG10201408392PA (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3
SG2011050994A SG172983A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011050994A SG172983A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Country Status (12)

Country Link
US (4) US8349574B2 (fr)
EP (1) EP2387711B1 (fr)
JP (1) JP5746051B2 (fr)
KR (1) KR20110120891A (fr)
CN (1) CN102460152B (fr)
AU (1) AU2010204583A1 (fr)
BR (1) BRPI1007321A2 (fr)
CA (1) CA2749846C (fr)
ES (1) ES2535723T3 (fr)
IL (1) IL214072A (fr)
SG (2) SG10201408392PA (fr)
WO (1) WO2010083470A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
WO2009070772A1 (fr) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Procédé amélioré de détection et/ou de quantification d'un analyte dans un échantillon
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
US11401344B2 (en) * 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
CA2764386C (fr) * 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings Anticorps p35-her2 et leurs utilisations
WO2010083463A1 (fr) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Procédés de détermination d'une réponse de patient par la mesure de l'expression de her-2
CA2749846C (fr) 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Procedes permettant de determiner la reponse d'un patient par mesure de her-3
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
WO2010132723A1 (fr) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarqueurs permettant de déterminer la sensibilité de cellules cancéreuses du sein à un traitement ciblant le récepteur her2
EP2488876B1 (fr) 2009-10-13 2017-03-01 Nanostring Technologies, Inc Détection de protéine par l'intermédiaire de nanorapporteurs
KR20120098911A (ko) 2009-12-22 2012-09-05 로슈 글리카트 아게 항-ｈｅｒ3 항체 및 이의 용도
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2833212C (fr) * 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
ES2615265T3 (es) 2011-05-19 2017-06-06 Laboratory Corporation Of America Holdings Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer
EP2736928B1 (fr) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Proteines "sur"-liantes dirigees contre erbb3
WO2013096828A1 (fr) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Protéines substitutives de liaison
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
DK3677271T3 (da) 2013-03-13 2023-05-22 Univ Miami Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider
EP2981828A1 (fr) * 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systèmes et procédés pour faciliter le diagnostic, le pronostic et le traitement d'un cancer sur la base de la détection de l'activation de her3
CN105593241B (zh) * 2013-10-04 2020-07-10 豪夫迈·罗氏有限公司 特异性结合her3的抗体
AU2015223567B2 (en) 2014-02-28 2020-09-10 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
EP3325650B1 (fr) 2015-07-17 2024-01-03 Nanostring Technologies, Inc. Quantification simultanée de l'expression génique dans une région définie par l'utilisateur d'un tissu en coupe transversale
WO2017015097A1 (fr) 2015-07-17 2017-01-26 Nanostring Technologies, Inc. Quantification simultanée d'une pluralité de protéines dans une région définie par l'utilisateur d'un tissu en coupe transversale
MX2018004988A (es) 2015-10-23 2018-11-09 Merus Nv Moleculas de union que inhibe el crecimiento de cancer.
US10451614B2 (en) 2016-03-15 2019-10-22 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
WO2018182422A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)
IL269655B2 (en) 2017-03-31 2023-09-01 Merus Nv An erbb-2-targeted agent and a bispecific antibody with antigen-binding sites that bind epitopes on the extracellular part of erbb-2 and erbb-3, for the treatment of individuals with erbb-2, erbb-2/erbb-3 positive cancer tumors
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CN112154216A (zh) 2018-02-12 2020-12-29 纳米线科技公司 生物分子探针以及检测基因和蛋白表达的方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5117165B1 (fr) 1973-12-27 1976-05-31
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0484027B1 (fr) 1990-11-02 1996-12-18 Zeneca Limited Phthalocyanines polysubstituées
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
DK0653066T3 (da) 1992-07-31 1998-09-23 Dade Behring Marburg Gmbh Fotoaktiverbare kemiluminescerende matricer
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US6204007B1 (en) 1994-03-29 2001-03-20 Celltech Therapeutics Limited Antibodies against E-selectin
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
SE9601676D0 (sv) 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6682887B1 (en) 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US20040248150A1 (en) 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US7037654B2 (en) 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US7001725B2 (en) 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US20030092012A1 (en) 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド 抗−ＥｒｂＢ２抗体による治療
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
CA2397772C (fr) * 2000-01-12 2007-06-12 Ventana Medical Systems, Inc. Procede de determination d'une reaction a une therapie anticancereuse
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
MY133839A (en) 2000-03-14 2007-11-30 Shell Int Research Process for the carbonylation of pentenenitrile
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US20030207300A1 (en) 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
WO2001084157A2 (fr) 2000-05-04 2001-11-08 Dade Behring Marburg Gmbh Compositions servant a la detection d'analytes multiples
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
EP1309717A1 (fr) 2000-08-08 2003-05-14 Aclara BioSciences, Inc. Dosages enzymatiques multiplexes
AU2001280222A1 (en) 2000-08-19 2002-03-04 Sung-Cheol Kim Communication line separator
EP1236740B1 (fr) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vaccin contre cancers associés à l'oncogène HER-2/neu
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
PL373962A1 (en) 2001-05-21 2005-09-19 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
US7041459B2 (en) 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
US7358052B2 (en) 2001-05-26 2008-04-15 Monogram Biosciences, Inc. Catalytic amplification of multiplexed assay signals
AU2002316577A1 (en) 2001-07-09 2003-01-29 Aclara Biosciences, Inc. Cell-screening assay and composition
WO2003055439A2 (fr) 2001-07-18 2003-07-10 The Regents Of The University Of California Antigene cible her2/neu et son utilisation pour stimuler une reponse immunitaire
WO2003008968A2 (fr) 2001-07-19 2003-01-30 Signet Laboratories, Inc. Procede de criblage de medicaments specifique pour le tissu humain
GB2378245A (en) 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
CA2456732C (fr) 2001-08-07 2012-10-30 Galephar M/F Composition pharmaceutique orale contenant une combinaison de ppar.alpha. et d'un inhibiteur de l'hmg-coa reductase
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
WO2003032867A1 (fr) 2001-10-12 2003-04-24 Gyne Ideas Limited Biomateriau comportant des microelements
WO2003033741A1 (fr) 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Amorce a marque electrophoretique universelle, compositions de sonde et procedes associes
US7045311B2 (en) 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
CA2465594C (fr) 2001-11-09 2012-02-07 Aclara Biosciences Inc. Compositions de microparticules marquees et procedes associes
WO2003042658A2 (fr) 2001-11-09 2003-05-22 Aclara Biosciences, Inc. Procedes et compositions permettant d'ameliorer la detection dans des analyses dans lesquelles on utilise des reactifs a marqueurs electrophoretiques clivables
WO2003042657A2 (fr) 2001-11-09 2003-05-22 Aclara Biosciences Inc. Detection de sequences d'acides nucleiques par clivage et separation de structures marquees
US7341362B2 (en) 2001-12-18 2008-03-11 Monogram Biosciences, Inc. Photoactivation device and method
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
DK1478667T3 (da) * 2002-02-26 2010-12-20 Sigma Tau Ind Farmaceuti Monoklonalt anti-humant tenascin-antistof
KR20040108655A (ko) 2002-03-05 2004-12-24 아클라라 바이오사이언시스 인코퍼레이티드 막-결합된 민감제를 사용하는 복합 분석법
CA2478850C (fr) 2002-03-13 2018-02-27 Genomic Health, Inc. Profilage d'expression genique dans des tissus tumoraux ponctionnes
WO2003085374A2 (fr) 2002-04-02 2003-10-16 Aclara Biosciences, Inc. Dosages multiplexes utilisant des marqueurs moleculaires separes par electrophorese
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20090111127A1 (en) 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040175765A1 (en) 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
CN102295703A (zh) * 2002-07-15 2011-12-28 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
WO2004011900A2 (fr) 2002-07-25 2004-02-05 Aclara Biosciences, Inc. Detection d'oligomerisation de recepteur
WO2004010842A2 (fr) 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Sondes electrophoretiques lipophiles
US20040091850A1 (en) 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
US7122319B2 (en) 2002-12-18 2006-10-17 Monogram Biosciences, Inc Multiplexed immunohistochemical assays using molecular tags
US20060127947A1 (en) 2003-01-17 2006-06-15 Maurizio Fusco Receptor deorphanization using tagged molecular libraries
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
US20100291594A1 (en) 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
EP1673399B1 (fr) 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detection et profilage de complexes moleculaires
WO2005017493A2 (fr) 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarqueurs contre le cancer
US20050106571A1 (en) 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
EP1681983A4 (fr) 2003-10-14 2008-12-10 Monogram Biosciences Inc Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie
EP1680666A4 (fr) 2003-10-27 2008-03-26 Monogram Biosciences Inc Detection d'anticorps anti-therapeutique humain
US7919086B2 (en) * 2004-07-09 2011-04-05 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
WO2006137932A2 (fr) 2004-11-03 2006-12-28 Leucadia Technologies, Inc. Detection homogene de substance a analyser
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
CA2601700A1 (fr) * 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Phosphorylation des proteines suivant des voies controlees par les egfr
WO2006084018A2 (fr) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Procede permettant de determiner la sensibilite a un traitement anticancereux
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2006133460A2 (fr) * 2005-06-09 2006-12-14 Yale University Methodes de diagnostic et de traitement du cancer du sein d'apres le rapport her/er
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (zh) 2005-09-09 2010-04-28 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
WO2007041502A2 (fr) * 2005-09-30 2007-04-12 Monogram Biosciences Procedes pour la determination de la sensibilite a la therapie cancereuse
JP2009532393A (ja) 2006-04-07 2009-09-10 コペンハーゲン ユニバーシティ ＥｒｂＢ受容体由来ペプチド断片
EP1997832A1 (fr) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
JP5117165B2 (ja) 2007-11-09 2013-01-09 花王株式会社 水中油型乳化組成物の製造方法
WO2009070772A1 (fr) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Procédé amélioré de détection et/ou de quantification d'un analyte dans un échantillon
CN101230390A (zh) 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CA2764386C (fr) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings Anticorps p35-her2 et leurs utilisations
CA2749846C (fr) 2009-01-15 2018-08-07 Laboratory Corporation Of America Holdings Procedes permettant de determiner la reponse d'un patient par mesure de her-3
WO2010083463A1 (fr) 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Procédés de détermination d'une réponse de patient par la mesure de l'expression de her-2

Also Published As

Publication number Publication date
EP2387711B1 (fr) 2015-04-22
CA2749846C (fr) 2018-08-07
AU2010204583A1 (en) 2011-08-25
AU2010204583A2 (en) 2011-09-01
JP2012515226A (ja) 2012-07-05
US20160061839A1 (en) 2016-03-03
EP2387711A1 (fr) 2011-11-23
EP2387711A4 (fr) 2012-07-18
SG172983A1 (en) 2011-08-29
JP5746051B2 (ja) 2015-07-08
US10775382B2 (en) 2020-09-15
CA2749846A1 (fr) 2010-07-22
BRPI1007321A2 (pt) 2018-07-10
US20130071859A1 (en) 2013-03-21
ES2535723T3 (es) 2015-05-14
WO2010083470A1 (fr) 2010-07-22
US20180164319A1 (en) 2018-06-14
US9110066B2 (en) 2015-08-18
CN102460152A (zh) 2012-05-16
US20100210034A1 (en) 2010-08-19
US9766242B2 (en) 2017-09-19
US8349574B2 (en) 2013-01-08
KR20110120891A (ko) 2011-11-04
CN102460152B (zh) 2014-11-26
IL214072A (en) 2016-08-31
IL214072A0 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
WO2010046443A3 (fr) Procédés pour la détection et le diagnostic d’un trouble osseux ou cartilagineux
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
WO2010065568A3 (fr) Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95
HK1202925A1 (en) Test sensor for determining analyte concentration in fluid sample
BR112012030788A2 (pt) métodos de detecção de anticorpos monoclonais para enzimas que conferem resistência ao ácido 2,4-diclorofenoxiacético em plantas
ATE554389T1 (de) Apex als marker für lungenkrebs
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
WO2014074835A3 (fr) Compositions d'anticorps et procédés d'immunodosage pour détecter des isoformes de l'hormone antimüllérienne
PL2021794T3 (pl) Zastosowanie białka S100A 12 jako markera raka okrężnicy i odbytnicy
EP2449129A4 (fr) Procédés pour déterminer la présence et/ou la concentration d un analyte dans un échantillon
NZ596659A (en) Bulbless spectrometer
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
HK1165001A1 (zh) 利用免疫法測定生物樣品中的雌馬酚的方法、用於該測定的試劑盒、以及判定受試者的雌馬酚產生能力的方法
PL2040072T3 (pl) System analityczny do określania koncentracji analitu w płynie ustrojowym
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
GB201014837D0 (en) Biomarker signatures and uses thereof
WO2005124356A3 (fr) Utilisation d'une proteine cbp2 en tant que marqueur pour un cancer colorectal
MY149500A (en) The quantitative determination of risedronate in urine by spe-lc-ms-ms
EP2383570A3 (fr) Dispositif de mesure, procédé de mesure et programme
WO2008131261A3 (fr) Biomarqueurs peptidiques de maladie cardiovasculaire
EP2120042A4 (fr) Éprouvette de mesure d'échantillon biologique, et dispositif de mesure d'échantillon biologique
WO2010097553A3 (fr) Procédé de diagnostic d'une vascularite
WO2010000467A8 (fr) Asc en tant que marqueur du cancer du poumon
MX341181B (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.